Contents

27 March 2019
Vol 11, Issue 485

About The Cover

Cover image expansion

ONLINE COVER Dialing Down Tau Pathology. Shown is a laser scanning confocal image of a coronal section through the brain of an rTg4510 mouse, a model of tauopathy. Tauopathies, neurodegenerative disorders that include Alzheimer's disease and frontotemporal dementia, are characterized by deposition of tau inclusions in the brain. Treating rTg4510 mice with an inhibitor of the enzyme farnesyltransferase resulted in clearance of mutant tau deposits through the lysosomal pathway (Hernandez et al.). Treated mice showed a decrease in tau inclusions (red), a decrease in activation of microglia (gray) and astrocytes (green), and improved cognitive function. Farnesyltransferase inhibitors have been shown to be safe in human patients in several clinical trials and could be moved quickly into clinical testing for tauopathies. [CREDIT: HERNANDEZ ET AL./SCIENCE TRANSLATIONAL MEDICINE]